⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431279 | 0.89 | HIF1A (0.33) | — | |
| SCHEMBL16878149 | 0.86 | EPAS1 (0.35) | — | |
| SCHEMBL16877600 | 0.83 | — | — | |
| SCHEMBL16877687 | 0.81 | L3MBTL1 (0.39) | — | |
| SCHEMBL18207538 | 0.78 | CCR5 (0.42) | — | |
| SCHEMBL18207911 | 0.78 | L3MBTL1 (0.37) | — | |
| SCHEMBL19358160 | 0.77 | — | — | |
| SCHEMBL21377501 | 0.76 | L3MBTL1 (0.36) | — | |
| SCHEMBL18780550 | 0.75 | L3MBTL1 (0.31) | — | |
| SCHEMBL21568738 | 0.73 | L3MBTL1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | claimed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | claimed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2020259724-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103583-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2068868-A2 | COMBINATION THERAPY | Genzyme Corporation (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008017025-A2 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |